{"id":32898,"date":"2025-09-22T10:21:12","date_gmt":"2025-09-22T14:21:12","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=32898"},"modified":"2026-04-07T10:17:57","modified_gmt":"2026-04-07T14:17:57","slug":"a-strategic-guide-to-pharmaceutical-patent-pool-participation","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/a-strategic-guide-to-pharmaceutical-patent-pool-participation\/","title":{"rendered":"Pharmaceutical Patent Pools: The Strategic Playbook Every Originator and Generic Needs Now"},"content":{"rendered":"\n

The conventional view of a pharmaceutical patent is simple: it is a monopoly right, a wall built to keep competitors out for long enough to recoup R&D investment and turn a profit. This framing has served the industry for decades. It also, increasingly, fails to capture how patents actually function as strategic instruments in a world where $350 billion in global drug revenues face patent expiration before 2030, where institutional investors price ESG compliance into cost of capital, and where a single pandemic can rewrite the rules of IP governance overnight [1, 12].<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Pharmaceutical patent pools occupy the productive middle ground between full exclusivity and forced access. They are not charity, and they are not expropriation. They are a legal architecture designed to solve a specific market failure: the ‘tragedy of the anti-commons,’ a term coined by economist Michael Heller to describe situations where overlapping property rights collectively block the productive use of a resource [1]. When three separate companies own the patents on three antiretroviral (ARV) compounds that clinicians want to combine into a single fixed-dose combination pill, no combination pill gets made. The transaction costs are too high, the legal risk too uncertain, and the commercial logic too unclear. The patients who need the pill lose.<\/p>\n\n\n\n

Patent pools fix this by consolidating licensing under a single neutral entity. Patent holders contribute their IP, the pool grants non-exclusive sublicenses to qualified manufacturers, and competition among those manufacturers drives prices down. This article is a systematic, data-grounded guide to how these mechanisms work, who participates, why they participate, what the terms look like, and how to integrate patent pool strategy into a company’s broader competitive intelligence function. The Medicines Patent Pool (MPP), the dominant public health-oriented pool in pharma, is the primary focus. But the principles transfer to any pooling structure your organization might encounter or consider creating.<\/p>\n\n\n\n

\n\n\n\n

Part One: The Problem Patent Pools Solve<\/strong><\/h2>\n\n\n\n

The Anti-Commons and the Fixed-Dose Combination Trap<\/strong><\/h3>\n\n\n\n

The 1994 World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) achieved something genuinely significant: it harmonized intellectual property protection across most of the global economy and gave innovators a predictable legal foundation for recouping R&D investment worldwide [1]. The unintended consequence, particularly acute in public health, was that it created patent thickets in therapeutic areas where multiple molecules must work together.<\/p>\n\n\n\n

Consider an HIV fixed-dose combination. Effective modern ARV regimens often require two or three molecular entities taken together, sometimes co-formulated into a single tablet that improves adherence and reduces treatment complexity. If Gilead holds the patent on compound A, ViiV Healthcare holds it on compound B, and a third party holds a formulation patent on the combination itself, a generic manufacturer must negotiate three separate licensing agreements. Each negotiation carries its own timeline, its own legal costs, and its own risk of failure [3]. The transaction costs frequently exceed whatever margin the generic could earn in low-income markets. So the pill never gets made at scale for the populations that need it most.<\/p>\n\n\n\n

This is the anti-commons in action: a situation where an abundance of property rights produces scarcity of access. Patent pools correct it by providing a single window through which a manufacturer can license multiple patents at once, under pre-negotiated terms, for a defined set of markets [3]. They convert a multi-party negotiation problem into a standardized commercial transaction.<\/p>\n\n\n\n

The concept is older than most executives realize. In 1856, a group of sewing machine manufacturers pooled their patents to end years of infringement litigation and redirect capital toward production. In 1917, the U.S. government orchestrated an aircraft patent pool to allow military manufacturers to build planes without each one suing the others [1]. The pharmaceutical adaptation carries the same logic, with an added dimension: the downstream beneficiaries are patients, and the stakes of failure are measured in deaths rather than commercial losses.<\/p>\n\n\n\n

TRIPS, Data Exclusivity, and the Compound Barrier<\/strong><\/h3>\n\n\n\n

A subtle but critical element of the access barrier extends beyond patents themselves. In many jurisdictions, regulatory data exclusivity gives originator companies a period of protection for the clinical trial data they submit to regulators, independent of any patent clock. A generic manufacturer seeking approval often cannot rely on the originator’s safety and efficacy data for a fixed period, which can run from five to twelve years depending on the jurisdiction and product type [9].<\/p>\n\n\n\n

This means a generic company could hold a valid patent license and still be blocked from regulatory approval by data exclusivity. Public health patent pools, including the MPP, address this directly. Standard MPP licenses include explicit data exclusivity waivers in the licensed territory, requiring the originator to permit regulators in those markets to rely on the original data when assessing the generic version [10]. Without this provision, a patent license alone would be insufficient to enable market entry.<\/p>\n\n\n\n

\n\n\n\n

Part Two: The Medicines Patent Pool \u2014 Architecture and Operations<\/strong><\/h2>\n\n\n\n

Origins: A Specific Crisis, a Specific Response<\/strong><\/h3>\n\n\n\n

The MPP was not a theoretical exercise. It was a direct response to the HIV\/AIDS crisis of the late 1990s and early 2000s, during which newly patented antiretrovirals were financially inaccessible to most patients in sub-Saharan Africa and South Asia. Civil society organizations, including Knowledge Ecology International (KEI) and M\u00e9decins Sans Fronti\u00e8res (MSF), began advocating for a pooled licensing mechanism that could aggregate patent rights and sublicense them to generic manufacturers willing to supply low- and middle-income countries (LMICs) [1].<\/p>\n\n\n\n

Unitaid, a global health initiative hosted by the World Health Organization (WHO), became the institutional home for the concept. With an initial investment of $4 million from Unitaid, the Medicines Patent Pool launched as an independent non-profit foundation in Geneva in July 2010, with a mandate focused exclusively on HIV medicines in developing countries [21].<\/p>\n\n\n\n

From that starting point, the MPP has expanded in deliberate, evidence-based stages:<\/p>\n\n\n\n

    \n
  • 2010-2015:<\/strong> HIV antiretrovirals. First licenses signed with Gilead Sciences and ViiV Healthcare, establishing that major pharmaceutical companies would participate voluntarily [21].<\/li>\n\n\n\n
  • 2015:<\/strong> Mandate expanded to hepatitis C (HCV) and tuberculosis (TB) [21].<\/li>\n\n\n\n
  • 2018:<\/strong> Broadened to any medicine on the WHO Model List of Essential Medicines, including non-communicable diseases (NCDs) such as cancer [19].<\/li>\n\n\n\n
  • 2020:<\/strong> Extended to COVID-19 treatments, including novel oral antivirals [19].<\/li>\n\n\n\n
  • 2021 onward:<\/strong> Expanded to foundational technology platforms, including mRNA vaccine manufacturing, positioning the MPP as an instrument for building regional manufacturing capacity rather than just licensing individual drugs [28].<\/li>\n<\/ul>\n\n\n\n

    Each expansion followed demonstrated success at the previous stage. The MPP did not enter cancer licensing without having built credibility through fifteen years of HIV, HCV, and TB work. That track record is why major pharmaceutical companies engage with it voluntarily.<\/p>\n\n\n\n

    How the MPP Actually Operates<\/strong><\/h3>\n\n\n\n

    The MPP’s operational model has five distinct phases, each with specific actors and specific incentive structures.<\/p>\n\n\n\n

    Phase 1: Prioritization<\/strong><\/h4>\n\n\n\n

    The process starts not with a patent but with a public health need. The MPP works with the WHO, clinical experts, civil society organizations, and patient communities to identify which medicines offer the greatest potential impact if access were improved [31]. It maintains a publicly available Priority and Watchlist of target medicines, which signals to the market where the MPP intends to negotiate and gives both originators and generic manufacturers advance notice to prepare [26].<\/p>\n\n\n\n

    This transparency is deliberate. An originator company that sees its product on the Priority List can initiate a conversation with the MPP before public pressure creates a less comfortable dynamic. A generic manufacturer that sees the same list can start building the technical and regulatory capabilities required to win a sublicense when it becomes available.<\/p>\n\n\n\n

    Phase 2: In-Licensing from the Patent Holder<\/strong><\/h4>\n\n\n\n

    Once a medicine is prioritized, the MPP’s business development team engages in confidential negotiations with the relevant patent holder [10]. These are bespoke, bilateral negotiations. There is no standard template that works unchanged for every product, though common structural elements recur across agreements.<\/p>\n\n\n\n

    The MPP positions itself explicitly as a non-confrontational partner. It is not a government threatening compulsory licensing; it is a neutral, non-profit intermediary offering a commercially structured voluntary arrangement [32]. This distinction matters enormously to legal and IP teams at originator companies who need to explain the decision internally.<\/p>\n\n\n\n

    Phase 3: Sublicensing \u2014 The Competitive Selection Process<\/strong><\/h4>\n\n\n\n

    Once an in-license is secured, the MPP issues a public call for Expressions of Interest (EOIs) from generic manufacturers. This typically runs for three to four weeks and requires applicants to submit a comprehensive proposal covering their technical capabilities, manufacturing capacity, regulatory history, API sourcing strategy, and commercialization plan [34].<\/p>\n\n\n\n

    The MPP assesses EOIs through a two-stage, blinded process. An initial evaluation panel scores each application against a standardized weighted rubric without knowing the company’s identity. Decision-makers at the final stage do not see company names during their assessment. The number of sublicenses granted is not unlimited; it reflects WHO-MPP projections of market demand, designed to ensure enough suppliers for competition without fragmenting demand below the threshold of commercial viability [36].<\/p>\n\n\n\n

    Phase 4: Manufacturing, Technology Transfer, and Supply<\/strong><\/h4>\n\n\n\n

    Sublicensees must develop their generic versions of the product and obtain WHO Prequalification (PQ) or approval from a recognized Stringent Regulatory Authority (SRA) before they can supply to major procurers [36]. For simple oral solid-dose generics, this primarily involves formulation development and bioequivalence studies. For complex products like biologics or long-acting injectables, it involves intensive technology transfer from the originator.<\/p>\n\n\n\n

    MPP sublicenses explicitly authorize manufacturers to develop new formulations \u2014 pediatric-friendly liquids, powders, fixed-dose combinations \u2014 that the originator may have no commercial incentive to develop itself [10]. This is where the pool generates value beyond simple price reduction: it enables the development of products that would otherwise never exist for LMIC patient populations.<\/p>\n\n\n\n

    Phase 5: Royalties and Impact Accounting<\/strong><\/h4>\n\n\n\n

    Generic sublicensees pay royalties to the MPP, which passes them to the originator. The structure is almost always tiered: royalty-free for low-income countries, and a rate between 5% and 10% of net sales for designated middle-income countries [11]. The MPP tracks supply volumes, cost savings, and estimated patient impact through audited reporting, publishing aggregate impact data annually [19].<\/p>\n\n\n\n

    This impact accounting matters strategically. When an originator’s communications or ESG team needs to quantify the public health benefit of the licensing decision, the MPP’s data provides audited, third-party evidence that converts a qualitative narrative into measurable outcomes.<\/p>\n\n\n\n

    Governance: Why It Works as a Neutral Intermediary<\/strong><\/h3>\n\n\n\n

    Any mechanism that asks pharmaceutical companies to voluntarily hand over IP, and access advocates to accept commercial royalties and geographic restrictions, faces an inherent trust problem. The MPP manages this through a multi-stakeholder governance structure that prevents capture by any single interest group.<\/p>\n\n\n\n

    The Governance Board includes individuals with deep expertise across the pharmaceutical sector, public health law, scientific research, and civil society [40]. Past board members have included Marie-Paule Kieny, former WHO Assistant Director-General, and Peter Maybarduk of Public Citizen, a consumer advocacy organization \u2014 representatives whose interests are structurally opposed in any bilateral negotiation [21]. The presence of both at the same governance table, approving the same license agreements, is what allows the MPP to credibly claim neutrality.<\/p>\n\n\n\n

    Supporting bodies include the Expert Advisory Group (EAG), which reviews proposed license terms; the Scientific Advisory Panel (SAP), which guides prioritization decisions based on clinical evidence; and the Community Advisory Panel (CAP), established in 2023, which brings direct input from people living with the diseases the MPP works on [39].<\/p>\n\n\n\n

    This architecture is not decorative. It is the mechanism through which the MPP earns the trust of originator companies skeptical of open licensing and access advocates skeptical of voluntary mechanisms. Without multi-stakeholder governance, the entire voluntary model fails.<\/p>\n\n\n\n

    \n\n\n\n

    Part Three: The Originator’s Decision \u2014 A Structured Business Analysis<\/strong><\/h2>\n\n\n\n

    The Entry Pathway Is Voluntary and Negotiated<\/strong><\/h3>\n\n\n\n

    Originator participation requires no formal application and carries no mandatory criteria. The process begins with a conversation between the MPP’s business development team and the patent holder, often initiated after the originator’s product appears on the MPP’s Priority List [32].<\/p>\n\n\n\n

    These are voluntary negotiations. The originator retains the right to walk away at any point. The terms of each license are the product of genuine bilateral negotiation, not a take-it-or-leave-it template imposed by the MPP. This distinction from compulsory licensing is the primary reason companies are willing to engage.<\/p>\n\n\n\n

    The Financial Business Case<\/strong><\/h3>\n\n\n\n

    Executives who dismiss patent pool participation as a CSR expenditure are reading the wrong P&L line. The financial case for engagement has at least four distinct components.<\/p>\n\n\n\n

    Royalty Revenues from Otherwise-Unreachable Markets<\/strong><\/p>\n\n\n\n

    The markets covered by MPP licenses are, almost by definition, markets where the originator has no meaningful commercial presence. A branded oral ARV at $15,000 per year per patient has no realistic demand in a country with GDP per capita of $1,500. An MPP license at a 5-10% royalty on generic net sales at $75 per patient per year generates revenue from a patient population the originator was not otherwise capturing [11].<\/p>\n\n\n\n

    A 2024 analysis by the Boston Consulting Group (BCG), commissioned by the MPP, estimated that voluntary licensing could generate between 2% and 17% of additional revenue for originators in upper-middle-income countries alone, by opening patient segments inaccessible at originator pricing [15]. The royalty stream is modest but predictable and carries essentially no sales force, marketing, or distribution cost for the originator.<\/p>\n\n\n\n

    Long-Term Market Shaping<\/strong><\/p>\n\n\n\n

    This is the financial argument that most originators undervalue. By licensing a foundational treatment to the MPP, an originator establishes the standard of care in dozens of LMICs. Diagnostic infrastructure gets built. Prescribers get trained. Patient populations get identified and enrolled in treatment programs. This market infrastructure remains in place when the originator’s next-generation product launches, and it is available to a brand that did not invest in building it.<\/p>\n\n\n\n

    The BCG analysis found that follow-on drugs from originators who had previously licensed a foundational product in a given market experienced up to four times the growth rate in those markets compared to categories where no prior market-shaping had occurred [15]. The voluntary license for dolutegravir (DTG) in 2014 created the HIV treatment infrastructure in Sub-Saharan Africa that later facilitated the introduction of long-acting injectable options, including cabotegravir LA (CAB-LA).<\/p>\n\n\n\n

    Operational Cost Avoidance<\/strong><\/p>\n\n\n\n

    The BCG-MPP report estimated that managing a bilateral access program for a single product across just 22 LMICs could cost an originator approximately $10 million in consultancy and partnership management fees [15]. The MPP manages sublicensee selection, agreement drafting, royalty collection, quality monitoring, and impact reporting. By partnering with the MPP, the originator outsources this entire function to a specialist non-profit with existing systems, relationships, and expertise.<\/p>\n\n\n\n

    Compulsory License Risk Mitigation<\/strong><\/p>\n\n\n\n

    Under Article 31 of the TRIPS agreement, WTO member governments retain the right to authorize a third party to use a patented invention without the patent holder’s consent, particularly in national emergency or public health situations [9]. A compulsory license imposes terms the patent holder did not negotiate and cannot reject. The process creates uncertainty, diplomatic friction, and a loss of control over how the IP is managed.<\/p>\n\n\n\n

    A voluntary license through the MPP is the preemptive alternative. Governments whose health ministries are aware of an MPP license covering their country have less political incentive to pursue a compulsory mechanism. The originator’s legal and government affairs teams can point to the voluntary agreement as evidence of responsible market conduct.<\/p>\n\n\n\n

    The Reputational and ESG Calculus<\/strong><\/h3>\n\n\n\n

    The rise of ESG investing has turned reputational metrics into financial ones. Institutional investors now screen pharmaceutical holdings using ESG frameworks in which access to medicines is a core component of the ‘S’ dimension. A company with a documented, audited record of expanding access to essential medicines through mechanisms like the MPP has a quantifiably stronger ESG profile than one that does not.<\/p>\n\n\n\n

    This is not an abstract claim. Access to capital and cost of borrowing are moving in response to ESG ratings. The BCG-MPP report explicitly noted the emerging link between voluntary licensing records and eligibility for Sustainability Linked Bonds (SLBs), financial instruments where the interest rate is tied to achieving pre-set ESG targets [15]. A company with a strong MPP partnership record has a credible basis for structuring favorable SLBs. <blockquote> ‘Modeling suggests that between 2015 and 2032, MPP licenses for HIV, HCV, and TB drugs alone will result in an additional 18.7 million patient-years of treatment and avert more than 700,000 deaths across low- and middle-income countries.’ \u2014 Medicines Patent Pool Value Report, 2024 [15] <\/blockquote><\/p>\n\n\n\n

    Risks That Require Honest Assessment<\/strong><\/h3>\n\n\n\n

    Completing the originator’s calculus requires a clear-eyed look at the downsides.<\/p>\n\n\n\n

    Revenue Cannibalization: The Gap Between Fear and Evidence<\/strong><\/p>\n\n\n\n

    The most commonly cited concern is that generic sales in LMICs will cannibalize the originator’s own sales, either in those markets or through gray-market re-importation into high-income markets. The evidence does not support this fear as a primary risk driver. BCG’s analysis of sales data across diabetes, oncology, and cardiovascular categories showed that originator and generic products in the same market typically serve different patient segments at different price points [15]. The generic reaches patients the originator’s pricing model would not touch.<\/p>\n\n\n\n

    Diversion risk \u2014 generic product packaged for low-income markets being re-sold in high-income markets \u2014 is real but manageable. MPP sublicenses contain strict anti-diversion provisions and the MPP actively monitors sublicensee sales activity [20]. Differentiated packaging and serialization further reduce the commercial attractiveness of diversion. BCG estimated that effective MPP license management prevents between $2 million and $8 million per country per year in potential diversion-related revenue loss for originators [15].<\/p>\n\n\n\n

    External Reference Pricing<\/strong><\/p>\n\n\n\n

    When a product is sold at dramatically reduced prices in any market, some high-income country payers use that price as an anchor for their own reimbursement negotiations. This is a genuine structural risk in the pharmaceutical market. Originators manage it through careful geographic scoping of the license, ensuring that the countries included are clearly distinct from high-income reference markets, and through regulatory frameworks in their home markets that explicitly exclude LMIC prices from reference calculations.<\/p>\n\n\n\n

    The Outsider Problem<\/strong><\/p>\n\n\n\n

    A patent pool covering only some of the patents needed for a treatment is structurally incomplete. If the MPP holds licenses from two out of three necessary patent holders, it cannot grant a complete license for a fixed-dose combination that requires all three. This limitation reduces the pool’s utility and can frustrate both generic manufacturers and public health objectives [9]. The MPP mitigates this through careful prioritization and by building relationships with all relevant patent holders before announcing a licensing initiative. But it cannot compel a reluctant patent holder to participate, and this remains a meaningful constraint on the model’s reach.<\/p>\n\n\n\n

    Inside a License: The Key Terms<\/strong><\/h3>\n\n\n\n

    Every MPP license is unique, but a consistent set of structural elements recurs across agreements. Understanding them is essential preparation for any executive entering negotiations.<\/p>\n\n\n\n

    Geographic Scope<\/strong><\/h4>\n\n\n\n

    The Territory clause defines which countries generic sublicensees may sell into. Standard MPP licenses cover 90 or more LMICs, typically derived from World Bank income classifications [37]. Originators typically seek to exclude upper-middle-income countries where they have active commercial operations or credible launch plans. The full country list is published as part of the MPP’s transparency commitment \u2014 which means access advocates scrutinize exclusions publicly, creating reputational pressure for broad geographic coverage.<\/p>\n\n\n\n

    Royalty Architecture<\/strong><\/h4>\n\n\n\n

    The standard structure: royalty-free for sales in low-income countries; 5-10% of net sales in specified middle-income countries [11]. For the CAB-LA license, for example, the middle-income royalty is 5% in public sector channels and 10% in the private sector across ten designated countries, including India, Ukraine, and Vietnam [37]. During the COVID-19 public health emergency, the licenses for molnupiravir and nirmatrelvir\/ritonavir were fully royalty-free in all low-income markets [21].<\/p>\n\n\n\n

    Non-Exclusivity and Multi-Supplier Competition<\/strong><\/h4>\n\n\n\n

    This is non-negotiable from the MPP’s public health standpoint. Every MPP license grants the pool the right to sublicense to multiple manufacturers simultaneously [10]. The resulting supplier competition is the primary mechanism for price reduction. An originator that wants exclusivity for a preferred generic partner cannot achieve it through the MPP \u2014 if that is the objective, a bilateral deal is the appropriate route.<\/p>\n\n\n\n

    Follow-On Innovation Rights<\/strong><\/h4>\n\n\n\n

    MPP sublicenses explicitly permit generic manufacturers to develop new formulations of the licensed molecule, including pediatric formulations and fixed-dose combinations with other medicines [10]. This provision is fundamental to the model’s ability to generate products tailored to LMIC patient needs. It also benefits originators by enabling the development of formulations they had no commercial incentive to create, potentially expanding the therapeutic utility of their molecule at no R&D cost.<\/p>\n\n\n\n

    Transparency: Public License Text<\/strong><\/h4>\n\n\n\n

    The full text of MPP license agreements, including all territorial and royalty provisions, is published on the MPP’s website [43]. This level of transparency is unusual in pharmaceutical licensing. It allows access advocates, governments, and media to scrutinize the terms, which creates reputational pressure for originator-friendly terms to be limited and access-friendly terms to be preserved. Companies considering MPP engagement should account for this public scrutiny from the outset.<\/p>\n\n\n\n

    \n\n\n\n

    Part Four: The Generic Manufacturer’s Gauntlet<\/strong><\/h2>\n\n\n\n

    Why the MPP Selects Rigorously<\/strong><\/h3>\n\n\n\n

    An MPP sublicense is a strategic asset. It provides access to a licensed technology, a defined multi-country market, and an implicit endorsement of quality and commercial reliability. The MPP grants this asset selectively because the credibility of the entire model depends on sublicensees performing at a level that satisfies procurement agencies, national health ministries, and the originator who trusted the pool with their IP.<\/p>\n\n\n\n

    The selection process is designed to serve two masters simultaneously: the originator, who needs assurance that their IP is in competent hands, and the downstream procurers like The Global Fund and PEPFAR, who need confidence in product quality and supply reliability. A sublicensee who fails to achieve WHO Prequalification, or who cannot maintain supply continuity, damages both relationships and reduces the MPP’s ability to negotiate future licenses.<\/p>\n\n\n\n

    The EOI process is therefore not a formality. It is a structured due diligence exercise with defined criteria, weighted scoring, and blind assessment to minimize favoritism.<\/p>\n\n\n\n

    The Expression of Interest Process<\/strong><\/h3>\n\n\n\n

    When the MPP announces a new in-license, it simultaneously opens a formal EOI process, typically for three to four weeks [34]. The EOI form covers two main areas:<\/p>\n\n\n\n

      \n
    1. Organizational capabilities:<\/strong> Company history, financial health, quality management systems, regulatory track record, manufacturing infrastructure, and supply chain management.<\/li>\n\n\n\n
    2. Product-specific proposal:<\/strong> R&D timelines for the specific molecule, manufacturing strategy including API sourcing, regulatory submission plan, and commercialization and distribution strategy across the licensed territory.<\/li>\n<\/ol>\n\n\n\n

      Applicants are scored blind, with specific weightings attached to each question. The number of sublicenses granted is determined by demand forecasts rather than by how many strong applications are received. If demand projections support three sublicensees, the top three scoring applications receive the offer, regardless of how many exceeded a minimum threshold.<\/p>\n\n\n\n

      Technical and Manufacturing Qualifications<\/strong><\/h3>\n\n\n\n

      A successful applicant must demonstrate that it has current capacity to manufacture the relevant product form at a scale sufficient to serve a meaningful share of projected LMIC demand [34]. For a standard oral tablet, this means established solid-dose manufacturing with GMP-compliant facilities and a track record of producing similar molecules at commercial scale.<\/p>\n\n\n\n

      For complex technologies \u2014 long-acting injectables, biologics, mRNA products \u2014 the bar is substantially higher. The applicant must demonstrate specialized infrastructure and scientific expertise appropriate to the product class. For the CAB-LA sublicense selection, for example, the MPP explicitly required proven capability in sterile injectable manufacturing, a significantly narrower qualification criterion than that applied to oral ARVs [47].<\/p>\n\n\n\n

      Applicants should also demonstrate R&D capabilities proportional to the work required. If the license anticipates development of new pediatric formulations or fixed-dose combinations, the EOI must present a credible plan for executing that development work, including timeline, resource allocation, and analytical methodology.<\/p>\n\n\n\n

      Quality and Regulatory Excellence<\/strong><\/h3>\n\n\n\n

      The non-negotiable requirement across every MPP sublicense is a commitment to achieve WHO Prequalification or approval from a recognized Stringent Regulatory Authority before commercial supply begins [36].<\/p>\n\n\n\n

      WHO Prequalification is a comprehensive assessment of a product’s quality, safety, and efficacy, combined with GMP inspections of the manufacturing facility. It is designed to give procurement agencies confidence that a product meets international quality standards regardless of the regulatory capacity of the country where it is manufactured. Major international procurers, including The Global Fund, UNICEF, and PEPFAR, generally require WHO PQ or equivalent SRA approval for the products they purchase.<\/p>\n\n\n\n

      Applicants should document their regulatory track record in detail. A history of successful WHO PQ submissions, FDA or EMA approvals, and a clean record of GMP inspections strengthens an EOI materially. A history of GMP warning letters, regulatory rejections, or quality-related product recalls will, rationally, reduce a score significantly.<\/p>\n\n\n\n

      Commercial and Financial Viability<\/strong><\/h3>\n\n\n\n

      Technical capacity to manufacture a product is necessary but not sufficient. The MPP requires applicants to demonstrate a credible plan for registering, distributing, and commercializing the product across the licensed territory [34].<\/p>\n\n\n\n

      The licensed territory for a typical MPP sublicense covers 90 or more countries spanning Sub-Saharan Africa, South and Southeast Asia, Latin America, and parts of Eastern Europe. No single manufacturer will have existing distribution infrastructure across all of these markets. Applicants need to articulate a realistic strategy for reaching key markets, identifying which they will enter directly, which through distribution partnerships, and which they will prioritize in early phases.<\/p>\n\n\n\n

      Financial health documentation \u2014 audited financial statements, credit ratings, evidence of access to capital for scale-up investment \u2014 is part of the standard EOI. The development and regulatory submission process for a complex product can take two to four years and require substantial upfront investment before any revenue is generated. The MPP needs confidence that applicants can sustain this investment period.<\/p>\n\n\n\n

      Technology Transfer: The New Baseline for Complex Products<\/strong><\/h3>\n\n\n\n

      The MPP’s first generation of licenses \u2014 oral small-molecule ARVs \u2014 required a patent license and perhaps some API characterization data. Generic chemists could often reverse-engineer the formulation from published literature and standard pharmaceutical development work. This model does not apply to biologics, long-acting injectables, or mRNA-based products.<\/p>\n\n\n\n

      For these technologies, the gap between holding a patent license and being able to manufacture a quality product is enormous. A long-acting injectable requires specific particle size distributions, specific excipient systems, specific sterile manufacturing conditions, and specific analytical methods for characterization and quality control. Without the originator’s active transfer of this knowledge and know-how, no generic manufacturer can independently replicate the product.<\/p>\n\n\n\n

      The MPP recognized this shift and made technology transfer a formal, structured element of its model for complex products [35]. This is an intensive, multi-year process that transfers knowledge, manufacturing protocols, analytical methods, and quality assurance systems from the originator (‘Sending Unit’) to the generic sublicensee (‘Receiving Unit’).<\/p>\n\n\n\n

      What a Receiving Unit Must Demonstrate<\/strong><\/h4>\n\n\n\n

      The EOI for a complex technology license requires applicants to demonstrate more than manufacturing capacity. They must show [35]:<\/p>\n\n\n\n

        \n
      • Scientists with postgraduate training in relevant technical disciplines (bioproduction, sterile manufacturing, chemical engineering as applicable)<\/li>\n\n\n\n
      • GMP-compliant infrastructure designed for the specific product class<\/li>\n\n\n\n
      • Project management capability for multi-year, cross-functional programs<\/li>\n\n\n\n
      • A documented history of successful technology transfer from external partners<\/li>\n\n\n\n
      • Organizational willingness to work transparently with the Sending Unit, including joint troubleshooting of manufacturing challenges<\/li>\n<\/ul>\n\n\n\n

        The CAB-LA sublicense selection in 2023 \u2014 ultimately awarded to Aurobindo, Cipla, and Viatris \u2014 reflects how narrow the eligible pool becomes when technology transfer requirements are applied to complex sterile injectables [47]. Not every generic company that can manufacture oral tablets qualifies for this class of product.<\/p>\n\n\n\n

        The mRNA Technology Transfer Programme<\/strong><\/h4>\n\n\n\n

        The most ambitious application of the technology transfer model is the WHO mRNA Technology Transfer Programme, in which the MPP is a key partner [28]. Launched in 2021, this programme established a manufacturing hub in South Africa \u2014 a consortium including Afrigen Biologics and Biovac \u2014 responsible for independently developing an mRNA vaccine manufacturing platform using publicly available Moderna sequence data, then transferring that complete platform to a network of ‘spoke’ partners across Africa, Southeast Asia, and Latin America.<\/p>\n\n\n\n

        The MPP’s role in this programme is IP management: tracking relevant patents, facilitating legal agreements between the hub and spoke partners, and ensuring that no IP barrier prevents the technology from moving through the transfer network [28]. This positions the MPP as an infrastructure component of pandemic preparedness rather than simply a drug licensing intermediary.<\/p>\n\n\n\n

        The programme has an explicit long-term objective: creating self-sufficient mRNA vaccine manufacturing capacity in LMICs that does not depend on future technology transfers from high-income country manufacturers. Whether it succeeds on that ambition will take a decade to determine. The institutional design is sound.<\/p>\n\n\n\n

        The Strategic Payoff for Sublicensees<\/strong><\/h3>\n\n\n\n

        For a generic manufacturer that successfully clears the EOI gauntlet, the returns are substantial across several dimensions.<\/p>\n\n\n\n

        Access to a 90-plus country market through a single licensing agreement, with pre-negotiated terms, eliminates the bilateral negotiation costs that would otherwise make multi-country entry prohibitively expensive. The MPP’s estimation, drawing on Unitaid analysis, is that the cost of independently negotiating licenses from multiple patent holders for a complex fixed-dose combination could easily exceed the commercial value of the resulting market [3].<\/p>\n\n\n\n

        Patent litigation risk \u2014 the dominant financial uncertainty for any generic company \u2014 is effectively eliminated in the licensed territory. The sublicense is a legal shield against infringement claims by the originator, which allows the manufacturer to plan capital investment and production scale-up without the uncertainty of potential injunctions [45].<\/p>\n\n\n\n

        The timing advantage is significant. MPP sublicenses are granted years before relevant patents expire in many licensed markets. The CAB-LA sublicense was granted in 2023, with cabotegravir patents holding in many covered markets until the 2030s. The three selected generic manufacturers are building manufacturing capacity and seeking regulatory approvals now, giving them a multi-year head start over generic competitors who will wait for patent expiry [47].<\/p>\n\n\n\n

        Being named an MPP sublicensee also functions as a quality signal in global health procurement markets. The Global Fund, PEPFAR, Unitaid, and UNICEF all procure products that meet WHO PQ standards and, implicitly, treat selection by the MPP as an indicator of organizational reliability. Winning one MPP sublicense opens commercial relationships with procurement agencies that can be leveraged for other product lines entirely.<\/p>\n\n\n\n

        \n\n\n\n

        Part Five: Case Studies That Illuminate the Model<\/strong><\/h2>\n\n\n\n

        Dolutegravir: The Proof of Concept<\/strong><\/h3>\n\n\n\n

        ViiV Healthcare’s dolutegravir (DTG) received FDA approval in August 2013. In July 2014 \u2014 eleven months later \u2014 ViiV signed a voluntary license with the MPP, covering 112 countries [53]. At the time, this was an unusually rapid move for a recently approved drug. The license enabled rapid development of generic formulations and, crucially, the development of a fixed-dose combination of tenofovir, lamivudine, and dolutegravir (TLD) that would become the global standard for first-line HIV treatment.<\/p>\n\n\n\n

        By 2017, generic TLD was available from MPP sublicensees at approximately $75 per person per year. By June 2020, 11 generic manufacturers held sublicenses for DTG, and supply had reached 106 countries [21].<\/p>\n\n\n\n

        A 2022 modeling study published in The Lancet Public Health estimated that voluntary licensing of DTG through the MPP would deliver an additional 15.5 million patient-years of treatment, avert more than 150,000 deaths, and save the global health system $3.1 billion by 2032 compared to a scenario without voluntary licensing [53]. These projections assumed continued scale-up of treatment programs supported by generic supply \u2014 a reasonable assumption given actual procurement trends.<\/p>\n\n\n\n

        The DTG case established that the MPP model could function at the scale required to shift global treatment standards. It also demonstrated the market-shaping argument: the HIV treatment infrastructure built in Sub-Saharan Africa through DTG generic supply created the platform for subsequent prevention and treatment innovations.<\/p>\n\n\n\n

        Cabotegravir LA: Licensing for Complexity<\/strong><\/h3>\n\n\n\n

        Cabotegravir long-acting (CAB-LA) is a long-acting injectable for HIV pre-exposure prophylaxis (PrEP), administered every two months. The clinical evidence for its efficacy, particularly for populations who struggle with daily pill adherence, is compelling. The manufacturing challenge is an order of magnitude more complex than oral tablet production: sterile injectables require specialized facilities, analytical methods, and formulation expertise that most generic manufacturers do not possess.<\/p>\n\n\n\n

        In July 2022, seven months after the first FDA approval of CAB-LA for PrEP, ViiV Healthcare signed an MPP license covering 90 countries [47, 54]. The speed reflected lessons from the DTG experience \u2014 early licensing shapes markets more effectively than late licensing. In March 2023, the MPP announced the first three sublicensees: Aurobindo (India), Cipla (India\/South Africa), and Viatris (global) [47].<\/p>\n\n\n\n

        The selection of three sublicensees for CAB-LA, compared to eleven for DTG, reflects the narrower technical qualification pool for sterile injectables. All three have proven sterile manufacturing capabilities. All three face substantial technology transfer work and regulatory timelines before they can supply.<\/p>\n\n\n\n

        The CAB-LA license is the model for how patent pools must evolve as the pharmaceutical pipeline moves toward complex modalities. It is no longer sufficient to have manufacturing capacity in generic terms; the required capabilities must be specific to the product class.<\/p>\n\n\n\n

        COVID-19 Antivirals: Speed Under Pressure<\/strong><\/h3>\n\n\n\n

        In October and November 2021, Merck and Pfizer signed MPP licenses for their respective novel oral COVID-19 antivirals \u2014 molnupiravir and nirmatrelvir\/ritonavir (Paxlovid) \u2014 before either drug had received full regulatory approval in their primary markets [21]. This reversed the typical sequence in which licensing discussions begin only after commercial launch in high-income markets.<\/p>\n\n\n\n

        The speed was a direct response to political and civil society pressure generated by the pandemic’s inequitable toll. Merck’s license led to sublicenses with 27 generic manufacturers; Pfizer’s led to 36 [21]. The licenses covered approximately 100 countries and were royalty-free during the WHO-designated public health emergency period.<\/p>\n\n\n\n

        The experience generated both operational lessons and unresolved criticisms. Operationally, the MPP demonstrated that it could process and execute a large number of sublicenses at unprecedented speed \u2014 an institutional capability that directly informs pandemic preparedness planning. The criticism centered on geographic exclusions. Several upper-middle-income countries \u2014 including Brazil, China, and Turkey \u2014 fell outside the licensed territories, leaving their populations unable to access the licensed generic supply [21]. This tension between originator commercial interests and universal access objectives is inherent to the voluntary model and does not resolve through institutional design alone.<\/p>\n\n\n\n

        The COVID-19 episodes also put the MPP alongside the WHO’s COVID-19 Technology Access Pool (C-TAP), launched in May 2020 with a far broader mandate to pool all COVID-19 health technology IP openly [16]. C-TAP attracted minimal pharmaceutical company participation. The more targeted, product-specific approach of the MPP proved far more effective at securing voluntary participation from industry, though it covered fewer countries and technologies than C-TAP’s architects had hoped [18].<\/p>\n\n\n\n

        Nilotinib: The First Cancer License<\/strong><\/h3>\n\n\n\n

        In October 2022, Novartis signed an MPP license for nilotinib, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) [25]. This was the MPP’s first-ever license for a cancer medicine and its first formal step into non-communicable diseases at scale. Four sublicense agreements for nilotinib were signed in 2023, the first sublicenses for a cancer treatment in the MPP’s history [39].<\/p>\n\n\n\n

        The nilotinib license covers 44 countries and addresses a market where the disease profile differs substantially from infectious diseases. CML patient populations are smaller. Treatment requires access to specialized diagnostics and hematology care infrastructure that is absent or limited in many LMICs. Price reduction through generic competition is necessary but not sufficient \u2014 building clinical capacity matters equally.<\/p>\n\n\n\n

        The nilotinib experience is a pilot for how the MPP model must adapt to NCD licensing. Aggregating demand in small, dispersed patient populations across dozens of markets requires different procurement mechanisms than those used for high-volume infectious disease treatments. The MPP’s willingness to experiment here is well-founded: the NCD burden in LMICs is growing faster than treatment capacity, and access to cancer medicines is among the starkest equity gaps in global health.<\/p>\n\n\n\n

        Daclatasvir: Impact, Limits, and Market Evolution<\/strong><\/h3>\n\n\n\n

        Bristol-Myers Squibb licensed daclatasvir, a direct-acting antiviral for hepatitis C, to the MPP in 2015 [21]. By June 2020, MPP sublicensees had supplied treatment in 30 countries, and a modeling study projected that the license would result in 428,000 additional patients treated and $107.6 million in cost savings [78].<\/p>\n\n\n\n

        The daclatasvir case also illustrates a limit of the voluntary model. BMS subsequently decided to withdraw daclatasvir from the market and allowed its patents to lapse, at which point all generic manufacturers could produce and sell the molecule without any license from anyone. The MPP’s license was valuable in the early years when patents were in force; its relative impact declined as the market naturalized. This is not a failure of the model \u2014 it is the expected behavior of an exclusivity-based system. But it underscores that patent pool impact is most significant in the years immediately following a product’s key patent protections, and declines as those protections erode through expiry or abandonment.<\/p>\n\n\n\n

        \n\n\n\n

        Part Six: Patent Intelligence as a Competitive Weapon<\/strong><\/h2>\n\n\n\n

        Moving from Reactive to Proactive<\/strong><\/h3>\n\n\n\n

        Most pharmaceutical companies manage patents reactively. The legal team monitors expiry dates, litigates infringement claims, and responds to compulsory licensing threats when they materialize. The business development team considers voluntary licensing when public pressure or ESG requirements make it expedient. This reactive posture leaves value on the table.<\/p>\n\n\n\n

        A proactive patent pool strategy begins years before an EOI is announced or a licensing discussion is initiated. It requires continuous intelligence about the patent landscape across therapeutic areas of interest, the regulatory status and pipeline of potential MPP priority medicines, and the competitive capabilities of other generic manufacturers likely to compete for the same sublicenses.<\/p>\n\n\n\n

        This is where specialized patent intelligence platforms become operationally essential tools rather than legal research utilities.<\/p>\n\n\n\n

        Using DrugPatentWatch to Inform Licensing Decisions<\/strong><\/h3>\n\n\n\n

        DrugPatentWatch<\/strong> aggregates patent data, regulatory approval records, Paragraph IV litigation history, exclusivity timelines, and generic manufacturer filing activity into a searchable, analyzable intelligence layer [12]. For companies engaged with or considering patent pool participation, the platform supports three distinct analytical functions.<\/p>\n\n\n\n

        For an originator deciding whether to license an asset to the MPP, DrugPatentWatch’s data enables a realistic assessment of the patent position in relevant LMIC markets. How robust is the patent coverage in India, South Africa, or Brazil? Are there filed Paragraph IV challenges or documented patent oppositions that suggest the exclusivity position is more fragile than it appears from the US perspective? What are the generic manufacturers with capacity in this therapeutic area already filing for?<\/p>\n\n\n\n

        An originator that discovers through this analysis that its patent position in five key LMIC markets is weaker than assumed has a materially stronger incentive to negotiate an MPP license preemptively, securing royalties and goodwill rather than risking a compulsory license or a successful patent challenge that yields nothing.<\/p>\n\n\n\n

        For a generic manufacturer, the function is different but equally high-value [12]. By monitoring the patent landscapes of drugs on the MPP’s Priority and Watchlist, a generic company can identify which technologies it needs to develop capabilities in before the EOI opens. If the analysis shows that long-acting injectables dominate the MPP’s three-year pipeline, a generic manufacturer with the strategic foresight to invest in sterile manufacturing expertise today will be positioned as a leading candidate when the relevant EOI is published. The MPP’s selection criteria heavily favor applicants who can demonstrate existing capability rather than a plan to develop it.<\/p>\n\n\n\n

        DrugPatentWatch also enables generic manufacturers to assess competitive positioning before submitting an EOI. Understanding how many other manufacturers with relevant technical capabilities exist in a given product category allows a realistic assessment of the probability of winning a sublicense and informs the resource allocation decision around EOI preparation.<\/p>\n\n\n\n

        Identifying White Spaces Through Patent Analytics<\/strong><\/h3>\n\n\n\n

        Beyond informing decisions about specific products, systematic patent analytics reveals structural patterns that can guide medium-term strategy. Areas of high patent density in therapeutic categories under-served by existing medicines represent potential targets for MPP engagement. Areas where key process or formulation patents are approaching expiry in LMIC markets indicate where generic opportunity may emerge without requiring an MPP license at all.<\/p>\n\n\n\n

        For originator companies, patent analytics can identify product candidates in development where proactive engagement with the MPP from early clinical stages \u2014 building voluntary licensing into the commercial strategy before launch \u2014 might produce better long-term outcomes than the traditional approach of maximum exclusivity followed by pressure-driven licensing negotiations.<\/p>\n\n\n\n

        This strategic framing, supported by continuous patent intelligence from platforms like DrugPatentWatch, transforms the patent pool from an external mechanism to be responded to into an internal strategic option that is planned for, evaluated regularly, and executed at the optimal moment in the product lifecycle.<\/p>\n\n\n\n

        \n\n\n\n

        Part Seven: The Evolving Landscape<\/strong><\/h2>\n\n\n\n

        Licensing Technology Platforms, Not Just Pills<\/strong><\/h3>\n\n\n\n

        The MPP’s mandate expansion to foundational technology platforms represents a qualitative change in what patent pools are being asked to do [19]. Licensing a single drug patent transfers the right to make a specific molecule. Licensing an mRNA manufacturing platform transfers the capacity to make an entire class of future products.<\/p>\n\n\n\n

        This upstream move responds directly to the COVID-19 pandemic’s lesson about concentrated manufacturing capacity. In early 2021, roughly 70% of COVID-19 vaccine manufacturing capacity was in high-income countries, which held 16% of the global population [16]. The political and epidemiological consequences of this concentration were severe. The mRNA Technology Transfer Programme, with the MPP managing IP, is a structural attempt to prevent the same dynamic from recurring for the next pandemic pathogen.<\/p>\n\n\n\n

        The implications for originator companies are significant. A decision to contribute a technology platform to a pooling mechanism like the WHO-MPP hub is categorically different from licensing a single drug. It potentially transfers competitive advantage in manufacturing or formulation technology to manufacturers who could eventually compete with the originator in high-income markets. The governance structures and license terms for platform contributions require substantially more careful negotiation than those for individual drug licenses.<\/p>\n\n\n\n

        NCDs: The Growing Access Gap<\/strong><\/h3>\n\n\n\n

        The cancer licensing initiative with nilotinib opened a territory where the MPP has no established operational playbook. Non-communicable diseases present fundamentally different market structures from infectious diseases, where high patient volumes across common demographic groups support robust generic competition.<\/p>\n\n\n\n

        Cancer treatment is often highly individualized, diagnostics are specialized and expensive, treatment administration requires trained personnel, and patient populations within any single country may be too small to support multiple competing generic suppliers. The standard MPP model of fostering price reduction through multi-supplier competition may need modification for oncology and other NCD categories.<\/p>\n\n\n\n

        The MPP has acknowledged this challenge and is actively exploring adaptations, including working with procurement agencies to aggregate demand across countries and identifying mechanisms for ensuring sustainable supply in low-volume markets. The nilotinib experience will generate the operational data needed to determine which elements of the model transfer to NCDs and which require redesign.<\/p>\n\n\n\n

        Antimicrobial Resistance: A Market Failure Problem<\/strong><\/h3>\n\n\n\n

        The antimicrobial resistance (AMR) challenge presents a structural problem the standard patent pool model does not solve. The problem with new antibiotics is not patent thickets blocking access; it is that the commercial market for a product that must be reserved for use only in the most severe cases is inherently small. This market failure means that pharmaceutical companies have insufficient incentive to develop new antibiotics, and generic manufacturers have insufficient incentive to take sublicenses for antibiotic production even if licenses are freely available.<\/p>\n\n\n\n

        The MPP has recognized that addressing AMR requires supplementary ‘pull’ incentives on top of IP licensing \u2014 volume guarantees, market entry rewards, or other mechanisms that make the economics viable for manufacturers regardless of actual sales volume [57]. This brings the patent pool model into contact with health technology assessment and pharmaceutical reimbursement policy in ways that go well beyond licensing negotiations. The MPP is exploring these adaptations, but the AMR challenge is likely to require a hybrid of patent pool mechanisms and public sector financial instruments that has not yet been fully designed.<\/p>\n\n\n\n

        Geopolitical Pressures and the Limits of Voluntarism<\/strong><\/h3>\n\n\n\n

        The voluntary nature of the MPP model, its greatest strength in building originator trust, is also its primary structural limitation. No mechanism can compel a patent holder to participate. If a key company refuses to engage, the pool covering a particular treatment may be structurally incomplete. The experience with COVID-19 vaccines \u2014 where the major mRNA vaccine manufacturers did not contribute their core IP to C-TAP or the MPP \u2014 illustrates this limit clearly [18].<\/p>\n\n\n\n

        Geopolitical pressure is an increasingly significant variable. Pharmaceutical companies operating in the current political environment face government scrutiny of IP practices in multiple high-income markets simultaneously, from the Inflation Reduction Act’s drug pricing provisions in the United States to national health technology assessment bodies in Europe applying increasing pressure on originator prices. This external pressure may, paradoxically, increase originator willingness to engage with voluntary mechanisms like the MPP, as demonstrated cooperation with global access objectives provides political cover in home markets facing their own access debates.<\/p>\n\n\n\n

        \n\n\n\n

        Key Takeaways<\/strong><\/h2>\n\n\n\n

        Patent pools correct a specific market failure.<\/strong> The anti-commons problem \u2014 overlapping patents blocking access to essential medicines and follow-on innovation \u2014 is a real structural inefficiency. The MPP is not an attack on the patent system; it is a mechanism designed to make the system work where market incentives alone produce perverse outcomes.<\/p>\n\n\n\n

        The originator’s decision is financial, not philanthropic.<\/strong> The business case includes royalty revenues from markets otherwise unreachable, long-term market shaping that multiplies the growth rate of follow-on products, operational cost avoidance worth tens of millions of dollars per product, compulsory license risk mitigation, and a documented ESG record with quantifiable implications for cost of capital.<\/p>\n\n\n\n

        Technology transfer has become the new licensing frontier.<\/strong> For oral small-molecule drugs, a patent license is sufficient. For biologics, long-acting injectables, and mRNA-based products, manufacturing know-how is the critical transfer. Generic manufacturers who cannot demonstrate technical capability specific to a complex product class will not be selected as sublicensees, regardless of their general manufacturing credentials.<\/p>\n\n\n\n

        The generic sublicense selection process is a competitive filter, not a formality.<\/strong> The blinded, weighted EOI assessment is designed to select the most capable manufacturers from a competitive field. The award of an MPP sublicense is a meaningful quality signal in global procurement markets and creates commercial advantages that extend well beyond the specific sublicensed product.<\/p>\n\n\n\n

        Patent intelligence determines whether you lead or follow.<\/strong> Companies that monitor the MPP’s Priority List, analyze relevant patent landscapes, and build required technical capabilities before an EOI opens will outperform reactive competitors. Platforms like DrugPatentWatch provide the data layer required to convert patent monitoring from a legal function into a strategic planning input.<\/p>\n\n\n\n

        The model is expanding into harder territory.<\/strong> NCDs, AMR, and technology platform licensing each require adaptations to the standard MPP model. Companies engaging with the MPP in these new areas should expect more complex negotiations, more bespoke license terms, and more novel governance structures than were required for first-generation infectious disease licenses.<\/p>\n\n\n\n

        Voluntarism is the model’s strength and its constraint.<\/strong> The entire system depends on originator willingness to engage. Geographic exclusions from licenses, refusals to participate, and the outsider problem all reflect this constraint. Understanding its limits is as important as understanding its capabilities.<\/p>\n\n\n\n

        \n\n\n\n

        Frequently Asked Questions<\/strong><\/h2>\n\n\n\n

        1. How does the MPP reconcile the tension between an originator’s interest in restricting territory and a government’s need for access when the licensed countries exclude a major emerging economy?<\/strong><\/p>\n\n\n\n

        This is the sharpest operational tension in the voluntary licensing model. When a country like Brazil, China, or Argentina falls outside the licensed territory for a COVID-19 antiviral or cancer drug, health ministries in those countries face a choice: pay originator prices, fund domestic generic development without a license (risking infringement claims), or invoke TRIPS compulsory licensing provisions. The MPP does not resolve this tension; it manages it. Its approach is to negotiate the broadest feasible territory while accepting that upper-middle-income countries with significant originator commercial presence will often be excluded as the price of securing voluntary participation. The transparency of published license terms allows governments, civil society, and the press to scrutinize which countries are excluded and apply pressure accordingly. Some companies, facing that scrutiny, have subsequently expanded territorial coverage. The mechanism is advocacy-dependent rather than structurally guaranteed, which means geographic coverage remains a function of the political will to maintain pressure.<\/p>\n\n\n\n

        2. What does the MPP’s ‘blinded’ EOI assessment actually mean in practice \u2014 and does it genuinely prevent favoritism?<\/strong><\/p>\n\n\n\n

        The blind process means that the initial scoring panel sees only anonymized application content, with company names and identifying information removed. This reduces the risk of assessors favoring known brands or well-connected companies. However, perfect blinding is difficult for well-differentiated applicants: a company that describes a manufacturing facility in a specific Indian state, a specific regulatory approval history, and a specific technology platform may be identifiable to a knowledgeable assessor even without a name attached. The MPP mitigates this by structuring the scoring rubric around objective criteria \u2014 specific timelines, specific regulatory milestones, documented financial metrics \u2014 that are less susceptible to subjective reinterpretation than qualitative assessments of ‘company reputation.’ The final selection is made by a different group than the initial scorers, adding an additional layer of procedural separation. The process is more transparent and more structured than most bilateral licensing selection processes in the pharmaceutical industry, even if it is not perfectly immune to all forms of institutional bias.<\/p>\n\n\n\n

        3. For a generic manufacturer based in a middle-income country that the MPP license covers as a supply source, what royalty obligations apply to domestic sales versus export sales?<\/strong><\/p>\n\n\n\n

        This distinction is more nuanced than the headline royalty structure suggests. MPP sublicenses define royalty obligations based on the country of sale (where the product is ultimately sold to the end user or procurer), not the country of manufacture. A manufacturer in India that exports product to a Sub-Saharan African country covered by the royalty-free tier pays no royalty on those exports. The same manufacturer selling the product domestically in India \u2014 if India falls in a royalty-bearing tier \u2014 pays the applicable rate on those domestic net sales. The manufacturer is required to track sales by destination and report disaggregated figures to the MPP, which audits these reports. Manufacturers operating across multiple markets with different royalty tiers need robust sales tracking systems that can segregate revenue by country of sale at the batch or shipment level. This is an operational requirement that applicants should address in their EOI.<\/p>\n\n\n\n

        4. How does an originator company structure its internal governance to manage the decision to license an asset to the MPP, given that it crosses IP, legal, business development, government affairs, and ESG functions simultaneously?<\/strong><\/p>\n\n\n\n

        The companies that navigate this most effectively treat the licensing decision as a cross-functional strategic project rather than a legal transaction. This typically means establishing a steering committee with representatives from IP, legal, business development, government affairs, and corporate affairs, with an executive sponsor at the VP or SVP level. The IP and legal teams contribute portfolio strength analysis and term negotiation. Business development contributes commercial market analysis, including the BCG-style modeling of royalty projections and market shaping scenarios. Government affairs contributes geopolitical risk assessment and an understanding of compulsory licensing dynamics in key LMIC markets. Corporate affairs or ESG teams contribute the reputational and investor-relations dimensions. The decision document that goes to the C-suite should synthesize all four dimensions into a single business case that presents the net strategic value of participation compared to the alternatives (including compulsory licensing risk and continued unilateral access programs). Companies that have done this well \u2014 ViiV Healthcare’s early DTG license being a notable example \u2014 typically built this cross-functional capability before the MPP approached them, so the internal decision process was not initiated under time pressure.<\/p>\n\n\n\n

        5. Are there product categories or therapeutic areas where the MPP model is structurally inappropriate, regardless of the drug’s public health importance?<\/strong><\/p>\n\n\n\n

        Yes, though the list is smaller than critics of voluntary licensing sometimes suggest. The model is poorly suited to ultra-rare diseases where the global patient population is too small to support even a single generic manufacturer at commercial scale \u2014 the economics of sublicensing simply do not work when annual global demand is measured in thousands of doses. It is also poorly suited, in its current form, to therapeutic areas where the primary barrier to access is not the cost of the medicine but the capacity to deliver it safely: advanced oncology treatments requiring specialized infusion facilities, for example, or gene therapies that require genetic testing and specialist clinical infrastructure. For these categories, lowering the drug cost through generic licensing may have negligible impact on actual patient access if the clinical infrastructure does not exist to administer the treatment. The MPP has been explicit about these limitations and is working with partners to explore complementary mechanisms \u2014 including diagnostic and infrastructure investment \u2014 that could make licensing impactful in categories where it otherwise would not be. For now, the model remains most effective for treatments with established clinical infrastructure and meaningful patient volumes at price points accessible through generic competition.<\/p>\n\n\n\n

        \n\n\n\n

        References<\/strong><\/h2>\n\n\n\n

        [1] Health Action International. (2020). The Medicines Patent Pool.<\/em> https:\/\/haiweb.org\/storage\/2020\/01\/The-Medicines-Patent-Pool.pdf<\/p>\n\n\n\n

        [2] Ashdin Publishing. (n.d.). Patent pools: Opportunities for innovation and access to essential medicine for under-served populations in the 21st century.<\/em> https:\/\/www.ashdin.com\/articles\/patent-pools-opportunities-for-innovation-and-access-to-essential-medicine-for-underserved-populations-in-the-21st-century-106205.html<\/p>\n\n\n\n

        [3] Bermudez, J., & ‘t Hoen, E. (2010). The UNITAID patent pool initiative: Bringing patents together for the common good. PLoS Medicine.<\/em> https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2842943\/<\/p>\n\n\n\n

        [4] Health Action International. (n.d.). The Medicines Patent Pool.<\/em> https:\/\/haiweb.org\/encyclopaedia\/medicines-patent-pool\/<\/p>\n\n\n\n

        [5] Public Citizen. (n.d.). The Medicines Patent Pool.<\/em> https:\/\/www.citizen.org\/wp-content\/uploads\/pc-statement-on-mpp.pdf<\/p>\n\n\n\n

        [7] Legalzoom. (n.d.). The pros and cons of using a patent pool.<\/em> https:\/\/www.legalzoom.com\/articles\/the-pros-and-cons-of-using-a-patent-pool<\/p>\n\n\n\n

        [9] UC Berkeley Law. (n.d.). Medicines Patent Pool: Questions and answers.<\/em> https:\/\/www.law.berkeley.edu\/files\/Q_A_ENGLISH_15_may_revised(1).pdf<\/p>\n\n\n\n

        [10] Cambridge University Press. (n.d.). Patent pooling in public health. In The Cambridge Handbook of Public-Private Partnerships, Intellectual Property Governance, and Sustainable Development.<\/em> https:\/\/www.cambridge.org\/core\/books\/cambridge-handbook-of-publicprivate-partnerships-intellectual-property-governance-and-sustainable-development\/patent-pooling-in-public-health\/4B80E32F35CB3DA1395F8D63BA31FD1A<\/p>\n\n\n\n

        [11] World Intellectual Property Organization. (2012). The Medicines Patent Pool.<\/em> https:\/\/www.wipo.int\/edocs\/mdocs\/mdocs\/en\/wipo_gc_lic_ge_12\/wipo_gc_lic_ge_12_ref_factsheet.pdf<\/p>\n\n\n\n

        [12] DrugPatentWatch. (2025). The patent playbook your lawyers won’t write: Patent strategy development framework for pharmaceutical companies.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/the-patent-playbook-your-lawyers-wont-write-patent-strategy-development-framework-for-pharmaceutical-companies\/<\/p>\n\n\n\n

        [15] Medicines Patent Pool. (2024). MPP Value Report 2024.<\/em> https:\/\/medicinespatentpool.org\/uploads\/2024\/05\/MPP_VALUE-Report_2024_EN_WEB.pdf<\/p>\n\n\n\n

        [16] World Health Organization. (n.d.). How WHO C-TAP works.<\/em> https:\/\/www.who.int\/initiatives\/covid-19-technology-access-pool\/what-is-c-tap<\/p>\n\n\n\n

        [18] The Guardian. (2021, January 22). WHO platform for pharmaceutical firms unused since pandemic began. https:\/\/www.theguardian.com\/world\/2021\/jan\/22\/who-platform-for-pharmaceutical-firms-unused-since-pandemic-began<\/p>\n\n\n\n

        [19] Medicines Patent Pool. (n.d.). About us.<\/em> https:\/\/medicinespatentpool.org\/who-we-are\/about-us<\/p>\n\n\n\n

        [20] Medicines Patent Pool. (2024). Voluntary licensing.<\/em> https:\/\/medicinespatentpool.org\/uploads\/2024\/05\/MPP_VALUE-Report_4PAger_EN_Web.pdf<\/p>\n\n\n\n

        [21] Wikipedia. (n.d.). Medicines Patent Pool.<\/em> https:\/\/en.wikipedia.org\/wiki\/Medicines_Patent_Pool<\/p>\n\n\n\n

        [25] Medicines Patent Pool. (2022). Annual Report 2022.<\/em> https:\/\/medicinespatentpool.org\/annual-report-2022\/<\/p>\n\n\n\n

        [26] Medicines Patent Pool. (2024). Priority and watchlist medicines for in-licensing.<\/em> https:\/\/medicinespatentpool.org\/uploads\/2024\/01\/MPP-prioritised-and-watchlist-medicines.pdf<\/p>\n\n\n\n

        [28] Medicines Patent Pool. (n.d.). mRNA resources.<\/em> https:\/\/medicinespatentpool.org\/what-we-do\/mrna-technology-transfer-programme\/resources<\/p>\n\n\n\n

        [31] Medicines Patent Pool. (n.d.). Business model.<\/em> https:\/\/medicinespatentpool.org\/who-we-are\/business-model<\/p>\n\n\n\n

        [32] Medicines Patent Pool. (n.d.). Partnering with MPP.<\/em> https:\/\/medicinespatentpool.org\/partners\/who-we-work-with<\/p>\n\n\n\n

        [34] Medicines Patent Pool. (n.d.). How to give or get a licence.<\/em> https:\/\/medicinespatentpool.org\/partners\/how-to-get-or-give-a-licence<\/p>\n\n\n\n

        [35] Medicines Patent Pool. (n.d.). Technology transfer.<\/em> https:\/\/medicinespatentpool.org\/what-we-do\/technology-transfer<\/p>\n\n\n\n

        [36] Unitaid. (n.d.). End-of-grant evaluation: Medicines Patent Pool (MPPII).<\/em> https:\/\/unitaid.org\/uploads\/End-of-grant-evaluation-Medicines-Patent-Pool-MPPII.pdf<\/p>\n\n\n\n

        [37] Medicines Patent Pool. (n.d.). Cabotegravir long-acting (LA) for HIV PrEP and treatment.<\/em> https:\/\/medicinespatentpool.org\/licence-post\/cabotegravir-long-acting-la-for-hiv-pre-exposure-prophylaxis-prep<\/p>\n\n\n\n

        [39] Medicines Patent Pool. (2023). MPP 2023 annual report.<\/em> https:\/\/medicinespatentpool.org\/news-publications-post\/mpps-2023-annual-report-demonstrates-continuing-success-of-voluntary-licensing<\/p>\n\n\n\n

        [40] Medicines Patent Pool. (n.d.). Governance and team.<\/em> https:\/\/medicinespatentpool.org\/who-we-are\/governance-teams<\/p>\n\n\n\n

        [43] Medicines Patent Pool. (n.d.). Statutes, policies and governance.<\/em> https:\/\/medicinespatentpool.org\/who-we-are\/statutes-by-laws-policies<\/p>\n\n\n\n

        [45] PatentPC. (n.d.). Understanding the role of patent pools in the healthcare industry.<\/em> https:\/\/patentpc.com\/blog\/understanding-the-role-of-patent-pools-in-the-healthcare-industry<\/p>\n\n\n\n

        [47] Medicines Patent Pool. (2023). MPP signs sublicences with Aurobindo, Cipla and Viatris for ViiV Healthcare’s long-acting HIV prevention medicine.<\/em> https:\/\/medicinespatentpool.org\/news-publications-post\/medicines-patent-pool-signs-sublicences-with-aurobindo-cipla-and-viatris-to-produce-generic-versions-of-viiv-healthcares-innovative-long-acting-hiv-prevention-medicine<\/p>\n\n\n\n

        [53] NAM\/aidsmap. (2022). Voluntary licensing via the Medicines Patent Pool is saving hundreds of thousands of lives.<\/em> https:\/\/www.aidsmap.com\/news\/feb-2022\/voluntary-licensing-medicines-patent-pool-saving-hundreds-thousands-lives<\/p>\n\n\n\n

        [54] ViiV Healthcare. (2022, July). ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement.<\/em> https:\/\/viivhealthcare.com\/en-us\/media-center\/news\/press-releases\/2022\/july\/viiv-healthcare-and-the-medicines-patent-pool\/<\/p>\n\n\n\n

        [57] ReAct. (2019). Medicines Patent Pool’s view on the role of licenses for antibiotics.<\/em> https:\/\/www.reactgroup.org\/news-and-views\/news-and-opinions\/year-2019\/medicines-patent-pools-view-on-the-role-of-licenses-for-antibiotics-world-intellectual-property-day\/<\/p>\n\n\n\n

        [78] Medicines Patent Pool. (n.d.). New study confirms MPP licences save money and lives.<\/em> https:\/\/medicinespatentpool.org\/news-publications-post\/new-study-confirms-mpp-licences-save-money-and-lives<\/p>\n","protected":false},"excerpt":{"rendered":"

        The conventional view of a pharmaceutical patent is simple: it is a monopoly right, a wall built to keep competitors […]<\/p>\n","protected":false},"author":1,"featured_media":35295,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-32898","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=32898"}],"version-history":[{"count":3,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32898\/revisions"}],"predecessor-version":[{"id":37879,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32898\/revisions\/37879"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/35295"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=32898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=32898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=32898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}